Clinical ophthalmology (Auckland, N.Z.) · 2025
Optimization of the Ocular Surface Prior to Cataract Surgery Using Cryopreserved Amniotic Membrane.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wongskhaluang Jeff
Аннотация
PURPOSE: To assess the benefit of cryopreserved amniotic membrane (cAM) in restoring corneal surface health prior to cataract surgery and enhancing post-operative refractive outcomes in patients with moderate to severe dry eye disease (DED).
METHODS: A prospective, repeated-measures, self-controlled study of 64 eyes with moderate to severe DED that were treated with cAM prior to cataract surgery. Biometry, topography, corneal staining (NEI scale), SPEED scores, and best corrected visual acuity (BCVA) were assessed before and after treatment and 1-month post-operatively. Primary outcome was refractive accuracy before and after treatment based on manifest refraction at 1 month post-operatively.
RESULTS: A total of 55 eyes of 37 patients (95% female) completed the study. SPEED scores and NEI scores significantly improved at 1- and 2-weeks post-treatment, with sustained benefit at 1 month post-operatively (P < 0.0001). Spherical equivalent was within ±0.25 D in 36% of eyes before and 70% of eyes after cAM treatment (P = 0.002); within ±0.5 D in 66% of eyes before and 94% of eyes after (P < 0.001); within ±0.75 D in 76% of eyes before and 98% of eyes after (P < 0.001); and within ±1D in 86% eyes before and 100% of eyes after (P = 0.016). Emmetropia was attained in 84% of eyes, and 93% (51/55) of eyes had 20/20 BCVA post-operatively.
CONCLUSION: Treatment with cAM prior to cataract surgery can significantly improve both signs and symptoms of moderate to severe DED, with continued improvement post-operatively. Furthermore, CAM may ultimately improve biometry accuracy, mitigating the risk of surgical delay.
METHODS: A prospective, repeated-measures, self-controlled study of 64 eyes with moderate to severe DED that were treated with cAM prior to cataract surgery. Biometry, topography, corneal staining (NEI scale), SPEED scores, and best corrected visual acuity (BCVA) were assessed before and after treatment and 1-month post-operatively. Primary outcome was refractive accuracy before and after treatment based on manifest refraction at 1 month post-operatively.
RESULTS: A total of 55 eyes of 37 patients (95% female) completed the study. SPEED scores and NEI scores significantly improved at 1- and 2-weeks post-treatment, with sustained benefit at 1 month post-operatively (P < 0.0001). Spherical equivalent was within ±0.25 D in 36% of eyes before and 70% of eyes after cAM treatment (P = 0.002); within ±0.5 D in 66% of eyes before and 94% of eyes after (P < 0.001); within ±0.75 D in 76% of eyes before and 98% of eyes after (P < 0.001); and within ±1D in 86% eyes before and 100% of eyes after (P = 0.016). Emmetropia was attained in 84% of eyes, and 93% (51/55) of eyes had 20/20 BCVA post-operatively.
CONCLUSION: Treatment with cAM prior to cataract surgery can significantly improve both signs and symptoms of moderate to severe DED, with continued improvement post-operatively. Furthermore, CAM may ultimately improve biometry accuracy, mitigating the risk of surgical delay.